Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493074 | 0.89 | OPRM1 (0.62) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6602014 | 0.88 | OPRM1 (0.57) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6865324 | 0.85 | OPRM1 (0.58) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6604934 | 0.84 | OPRM1 (0.55) | OPRM1OPRK1OPRD1 | |
| SCHEMBL7645587 | 0.83 | OPRM1 (0.52) | OPRM1OPRK1OPRD1 | |
| SCHEMBL7645593 | 0.83 | OPRM1 (0.52) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6492607 | 0.83 | OPRM1 (0.58) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6485486 | 0.83 | OPRM1 (0.58) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6654876 | 0.82 | OPRM1 (0.73) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6654874 | 0.82 | OPRM1 (0.73) | OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085456-A1 | Compounds useful in therapy | PFIZER, INC. (US) | 2005-04-21 | — | — | US | disclosed |
| US-6812236-B2 | FOR THERAPY OF PRUTIUS | PFIZER INC. | 2004-11-02 | — | — | US | disclosed |
| US-20020099216-A1 | Compounds useful in therapy | PFIZER INC. | 2002-07-25 | — | — | US | disclosed |
| EP-1072592-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085456-A1 | Compounds useful in therapy | OPRL1, OPRD1, BDKRB1 | OPRM1 5/4885OPRK1 9/4885OPRD1 2/4885 |
| US-20020099216-A1 | Compounds useful in therapy | OPRD1, OPRL1, OPRM1 | OPRM1 3/4885OPRK1 4/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.